The case for personalized medicine

Journal of Diabetes Science and Technology

Volumn 3, Issue 4, 2009, Pages 680-684

  Abrahams, Edward ^a   Silver, Mike ^b  

^a Personalized Medicine Coalition   (United States)

^b Synaptix Communications   (United States)

Author keywords

Evidence based medicine; Molecular diagnostics; Personalized medicine; Pharmacogenomics; Preventive medicine; Regulation

Indexed keywords

HUMAN; HUMAN GENOME; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PHARMACOGENETICS; REVIEW;

GENOME, HUMAN; HUMANS; INDIVIDUALIZED MEDICINE; PATIENT COMPLIANCE; PHARMACOGENETICS;

EID: 77953054445     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680900300411     Document Type: Conference Paper

References (21)

1. President's Council of Advisors on Science and Technology. Priorities for personalized medicine. September 2008. http://www.ostp.gov/galleries/PCAST/ pcast-report-v2.pdf. Accessed June 19, 2009.
2. U.S. Food and Drug Administration. Table of valid biomarkers in the context of approved drug labels. http://www.fda.gov/Drugs/ScienceResearch/ ResearchAreas/Pharmacogenetics/ucm083378.htm. Accessed June 19, 2009.
3. Nelson HD, Huffman LH, Fu R, Harris EL, U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2005;143(5):362-79.
4. National Cancer Institute. BRCA1 and BRCA2: cancer risk and genetic testing. http://www.cancer.gov/cancertopics/factsheet/risk/brca. Accessed May 27, 2009.
5. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336(20):1401-8. (Pubitemid 27208598)
6. Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Eisner MP, Horner MJ, Howlader N, Hayat M, Hankey BF, Edwards BK. SEER cancer statistics review, 1975-2003. Bethesda: National Cancer Institute; 2006.
7. Zhang W, Ratain MJ, Dolan ME. The HapMap resource is providing new insights into ourselves and its application to pharmacogenomics. Bioinform Biol Insights. 2008;2:15-23
8. Broad Institute. New genomic tool for diabetes. February 12, 2007. http://www.broad.mit.edu/news/159. Accessed May 27, 2009.
9. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med. 2001;7(5):201-4. (Pubitemid 32822891)
10. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Eng J Med. 2005;353(16):1673-84. (Pubitemid 41464706)
11. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Eng J Med. 2005;353(16):1659-72.
12. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42(7):1017-25.
13. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 2001;286(18):2270-9. (Pubitemid 33063150)
14. Special report: genotyping for cytochrome P450 polymorphisms to determine drug-metabolizer status. Technol Eval Cent Asses Program Exec Summ. 2004;19(9):1-2.
15. U.S. Food and Drug Administration. FDA approves updated warfarin (Coumadin) prescribing information. August 16, 2007. http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/2007/ucm108967.htm. Accessed June 19, 2009.
16. Umans-Eckenhausen MA, Defesche JC, van Dam MJ, Kastelein JJ. Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia. Arch Intern Med. 2003;163(1):65-8. (Pubitemid 36091602)
17. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639-48. (Pubitemid 29415219)
18. Looking forward, looking back. Nat Biotechnol. 2008;26(5):475.
19. McWilliam A, Lutter R, Nardinelli C. Health care savings from personalizing medicine using genetic testing: the case of warfarin. 2006. http://aei-brookings.org/admin/authorpdfs/redirect-safely.php?fname=..pdffiles/ WP06-23-topost.pdf. Accessed May 27, 2009.
20. OncotypeDX. Has the economic validity of the Oncotype DX® assay been investigated? http://www.oncotypedx.com/ManagedCareOrgs/EconomicValidity.aspx? Sid=25. Accessed May 27, 2009.
21. Shankaran V. Conference presentation at the Gastrointestinal Cancers Symposium January 2009. San Francisco, California. http://www.medscape.com/ viewarticle/586946. Accessed May 27, 2009. Requires free registration to access.